Key Points
ALNEV.PA trades at €0.0002 with 155M shares and strong sell rating
Neovacs faces negative earnings, depleted cash, and failed vaccine pipeline
Technical indicators show oversold conditions with sustained selling pressure
Company lacks capital to fund clinical trials and operations
Neovacs S.A. (ALNEV.PA) trades at just €0.0002 per share on EURONEXT this pre-market session. The Paris-based biotechnology company faces extreme headwinds with a market cap of only €95 and a strong sell rating from analysts. ALNEV.PA stock has collapsed 99.99% over the past year, reflecting severe operational and financial challenges. The company develops therapeutic vaccines using its proprietary Kinoid technology for autoimmune and cancer treatments. With 155 million shares trading today, we examine what’s driving this distressed biotech stock and what investors need to know.
ALNEV.PA Stock Price and Trading Activity
ALNEV.PA stock opened at €0.0004 today with a day high of €0.0006 and low of €0.0002. The stock shows zero change from the previous close of €0.0002. Volume surged to 155 million shares, representing 5.18 times the average daily volume of 30 million. This massive relative volume spike suggests forced liquidation or panic selling among remaining shareholders.
The 50-day moving average sits at €0.000872, while the 200-day average is €0.18785. These diverging averages highlight the stock’s catastrophic decline. The year-to-date loss stands at 97.7%, with a 99.99% drop over the past 12 months. The 52-week range spans from €0.0002 to €35.0, showing the stock’s historic collapse from higher valuations.
Financial Metrics and Valuation Collapse
Neovacs S.A. reports negative earnings per share of €-221.36, making traditional valuation metrics meaningless. The price-to-sales ratio of 0.00026 appears cheap but masks fundamental insolvency. The company’s current ratio of 0.63 indicates it cannot cover short-term obligations with current assets.
Working capital stands at negative €1.49 million, while net current asset value is negative €1.50 million. Return on equity is negative 106%, and return on assets is negative 149%. These metrics confirm the company burns cash without generating revenue. The debt-to-market cap ratio of 2,424 shows liabilities dwarf the company’s market value. Track ALNEV.PA on Meyka for real-time updates on this distressed biotech situation.
Market Sentiment and Technical Signals
The RSI of 26.09 signals oversold conditions, yet the stock continues falling. The ADX of 45.30 indicates a strong downtrend with conviction. Williams %R at negative 100 shows maximum selling pressure. The rate of change is negative 50%, confirming accelerating downside momentum.
On-balance volume is deeply negative at €-458 million, reflecting sustained selling. The MACD histogram at zero shows momentum has completely stalled. These technical indicators paint a picture of capitulation, where remaining investors exit at any price. The stock’s extreme illiquidity and negative sentiment create dangerous conditions for any remaining shareholders.
Neovacs Pipeline and Strategic Challenges
Neovacs develops IFNa Kinoid, an anti-interferon alpha vaccine in Phase IIb trials for systemic lupus erythematosus. The company also pursues Phase IIa testing for dermatomyositis treatment. VEGF-Kinoid remains in preclinical stages for age-related macular degeneration and solid tumors. IL-4/IL-13 Kinoid targets allergies in preclinical development.
The company collaborates with Sunnybrook Research Institute on VEGF Kinoid for colorectal and ovarian cancer. However, clinical progress has stalled, and the company lacks capital for continued development. With only €2.50 cash per share and negative operating cash flow of €-20.64 per share, Neovacs cannot fund its pipeline. The last earnings announcement was in October 2019, indicating years without material updates to investors.
Final Thoughts
ALNEV.PA stock is in severe distress. Trading at €0.0002 with a €95 market cap, Neovacs faces existential challenges with negative profitability and depleted cash reserves. The company failed to commercialize its Kinoid vaccine platform despite once showing promise. With a strong sell rating and limited recovery prospects, this represents an extreme speculative risk. High trading volume likely reflects forced selling, not improvement. This stock is only for investors who can afford total capital loss.
FAQs
Neovacs failed to advance its vaccine pipeline commercially, burned through cash reserves, and reported negative earnings. The company lacks funding for clinical trials and operations, forcing a near-total collapse in shareholder value.
Kinoid is Neovacs’ proprietary platform for developing therapeutic vaccines targeting autoimmune, inflammatory, and cancer diseases. The technology has shown promise in preclinical and early clinical stages but has not achieved commercial success or regulatory approval.
No. The stock carries extreme risk with negative cash flow, depleted reserves, and a strong sell rating. This price reflects distress, not opportunity. Only speculative investors should consider this, understanding total loss is possible.
The C- grade indicates poor financial health across multiple metrics. The stock scores 1 out of 10 on DCF valuation, ROE, ROA, and price-to-book ratios, earning a strong sell recommendation from Meyka’s analysis system.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)